About David Rockwell

David Rockwell represents non-U.S. companies and financial institutions in
connection with their corporate finance and mergers and acquisitions
activities.
In the corporate finance area, he has acted on behalf of both underwriters
and issuers in connection with a wide range of high-profile equity and debt
financing transactions. His recent equity experience includes representing
UBS in connection with its implementation of a new holding company
structure, as well as representing the issuers in numerous IPOs, including
Braas Monier Building Group and LEG Immobilien. He has
represented Porsche, ING, SEB, Anheuser-Busch InBev and UBS in
connection with their various rights offerings, Evonik on its Frankfurt Stock
Exchange listing and Anheuser-Busch InBev on its New York Stock
Exchange listing. He has represented the underwriters in connection with
the IPOs of IMCD N.V., Allied Minds PLC, and Countrywide PLC, among
many others, as well as in connection with Commerzbank’s 2013 equity
rights offering, 2011 mandatory convertible bond offering and 2011 equity
rights offering, the 2013 equity offering and Frankfurt Stock Exchange
listing of the RTL Group, and the 2015 $6 billion Yankee bond issuance by
AstraZeneca.
Mr. Rockwell also regularly advises several European banks on U.S.
regulatory matters.
Mr. Rockwell is an officer of the IBA’s Capital Markets Forum and
immediate past Chairman of the IBA’s Securities Law Committee. He is a
member of the Consultative Advisory Group of the International Auditing
and Assurance Standards Board and a contributing editor to the IFLR.